Click for best price
Agerelated Macular Degeneration ARMD Drugs Market Size, Share 2023
| Market size in 2022 |
US$ 7949.4 million
|
Forecast Market size by 2029 |
US$ 9754.6 million
|
| Growth Rate |
CAGR of 3.0% |
Number of Pages |
69 Pages |
The global Age-relatedMacularDegeneration (ARMD) Drugs market was valued at US$ 7949.4 million in 2022 and is projected to reach US$ 9754.6 million by 2029, at a CAGR of 3.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for ?straight-ahead? activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
This report aims to provide a comprehensive presentation of the global market for Age-relatedMacularDegeneration (ARMD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-relatedMacularDegeneration (ARMD) Drugs. This report contains market size and forecasts of Age-relatedMacularDegeneration (ARMD) Drugs in global, including the following market information:
- Global Age-relatedMacularDegeneration (ARMD) Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
- Global top five companies in 2022 (%)
North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
We surveyed the Age-relatedMacularDegeneration (ARMD) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Type, 2022 (%)
- Anti VEGF Drugs
- Photosensitive Drugs
- Others
Global Age-relatedMacularDegeneration (ARMD) Drugs Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, by Application, 2022 (%)
- Exudative ARMD
- Atrophy ARMD
Global Age-relatedMacularDegeneration (ARMD) Drugs Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Age-relatedMacularDegeneration (ARMD) Drugs revenues share in global market, 2022 (%)
Key players include:
- Roche
- Regeneron Pharmaceuticals
- Bayer
- Santen Oy
- Kanghong Pharmaceuticals
- Novartis
- Eli Lilly and Company
- TRACON Pharmaceuticals
- Pfizer
- GSK
- BIOCAD
Outline of Major Chapters:
Chapter 1: Introduces the definition of Age-relatedMacularDegeneration (ARMD) Drugs, market overview.
Chapter 2: Global Age-relatedMacularDegeneration (ARMD) Drugs market size in revenue.
Chapter 3: Detailed analysis of Age-relatedMacularDegeneration (ARMD) Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Age-relatedMacularDegeneration (ARMD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Age-related Macular Degeneration (ARMD) Drugs Market, Global Outlook and Forecast 2023-2032 |
| Market size in 2022 |
US$ 7949.4 million
|
| Forecast Market size by 2029 |
US$ 9754.6 million
|
| Growth Rate |
CAGR of 3.0% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
69 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Age-relatedMacularDegeneration (ARMD) Drugs Overall Market Size
2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size: 2022 VS 2032
2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market
3.2 Top Global Age-relatedMacularDegeneration (ARMD) Drugs Companies Ranked by Revenue
3.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Age-relatedMacularDegeneration (ARMD) Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market
3.6.1 List of Global Tier 1 Age-relatedMacularDegeneration (ARMD) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Markets, 2022 & 2032
4.1.2 Anti VEGF Drugs
4.1.3 Photosensitive Drugs
4.1.4 Others
4.2 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts
4.2.1 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2023
4.2.2 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2024-2032
4.2.3 By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2022 & 2032
5.1.2 Exudative ARMD
5.1.3 Atrophy ARMD
5.2 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts
5.2.1 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2023
5.2.2 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2024-2032
5.2.3 By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2022 & 2032
6.2 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue & Forecasts
6.2.1 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2023
6.2.2 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2024-2032
6.2.3 By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.3.2 US Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.3.3 Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.3.4 Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.4.2 Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.3 France Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.4 U.K. Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.5 Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.6 Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.7 Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.4.8 Benelux Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.5.2 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.4 South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.5 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.5.6 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.6.2 Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.6.3 Argentina Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032
6.7.2 Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7.3 Israel Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7.4 Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
6.7.5 UAE Age-relatedMacularDegeneration (ARMD) Drugs Market Size, 2018-2032
7 Age-relatedMacularDegeneration (ARMD) Drugs Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.1.4 Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Regeneron Pharmaceuticals
7.2.1 Regeneron Pharmaceuticals Company Summary
7.2.2 Regeneron Pharmaceuticals Business Overview
7.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.2.4 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.2.5 Regeneron Pharmaceuticals Key News & Latest Developments
7.3 Bayer
7.3.1 Bayer Company Summary
7.3.2 Bayer Business Overview
7.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.3.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.3.5 Bayer Key News & Latest Developments
7.4 Santen Oy
7.4.1 Santen Oy Company Summary
7.4.2 Santen Oy Business Overview
7.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.4.4 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.4.5 Santen Oy Key News & Latest Developments
7.5 Kanghong Pharmaceuticals
7.5.1 Kanghong Pharmaceuticals Company Summary
7.5.2 Kanghong Pharmaceuticals Business Overview
7.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.5.4 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.5.5 Kanghong Pharmaceuticals Key News & Latest Developments
7.6 Novartis
7.6.1 Novartis Company Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.6.4 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.6.5 Novartis Key News & Latest Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Company Summary
7.7.2 Eli Lilly and Company Business Overview
7.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.7.4 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.7.5 Eli Lilly and Company Key News & Latest Developments
7.8 TRACON Pharmaceuticals
7.8.1 TRACON Pharmaceuticals Company Summary
7.8.2 TRACON Pharmaceuticals Business Overview
7.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.8.4 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.8.5 TRACON Pharmaceuticals Key News & Latest Developments
7.9 Pfizer
7.9.1 Pfizer Company Summary
7.9.2 Pfizer Business Overview
7.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.9.4 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.9.5 Pfizer Key News & Latest Developments
7.10 GSK
7.10.1 GSK Company Summary
7.10.2 GSK Business Overview
7.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.10.4 GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.10.5 GSK Key News & Latest Developments
7.11 BIOCAD
7.11.1 BIOCAD Company Summary
7.11.2 BIOCAD Business Overview
7.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Major Product Offerings
7.11.4 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global Market (2018-2023)
7.11.5 BIOCAD Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Age-relatedMacularDegeneration (ARMD) Drugs Market Opportunities & Trends in Global Market
Table 2. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers in Global Market
Table 3. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints in Global Market
Table 4. Key Players of Age-relatedMacularDegeneration (ARMD) Drugs in Global Market
Table 5. Top Age-relatedMacularDegeneration (ARMD) Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Type
Table 9. List of Global Tier 1 Age-relatedMacularDegeneration (ARMD) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Age-relatedMacularDegeneration (ARMD) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Age-relatedMacularDegeneration (ARMD) Drugs Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2024-2032
Table 30. Roche Company Summary
Table 31. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 32. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. Regeneron Pharmaceuticals Company Summary
Table 35. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 36. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Regeneron Pharmaceuticals Key News & Latest Developments
Table 38. Bayer Company Summary
Table 39. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 40. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Bayer Key News & Latest Developments
Table 42. Santen Oy Company Summary
Table 43. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 44. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Santen Oy Key News & Latest Developments
Table 46. Kanghong Pharmaceuticals Company Summary
Table 47. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 48. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Kanghong Pharmaceuticals Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 52. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Eli Lilly and Company Company Summary
Table 55. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 56. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Eli Lilly and Company Key News & Latest Developments
Table 58. TRACON Pharmaceuticals Company Summary
Table 59. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 60. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. TRACON Pharmaceuticals Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 64. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. GSK Company Summary
Table 67. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 68. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. GSK Key News & Latest Developments
Table 70. BIOCAD Company Summary
Table 71. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product Offerings
Table 72. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. BIOCAD Key News & Latest Developments
List of Figures
Figure 1. Age-relatedMacularDegeneration (ARMD) Drugs Segment by Type in 2022
Figure 2. Age-relatedMacularDegeneration (ARMD) Drugs Segment by Application in 2022
Figure 3. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2022
Figure 8. By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 9. By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 10. By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 12. By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 14. By Region - Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 15. By Country - North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 16. US Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 20. Germany Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 21. France Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 28. China Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 32. India Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 34. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share, 2018-2032
Figure 37. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Age-relatedMacularDegeneration (ARMD) Drugs Revenue, (US$, Mn), 2018-2032
Figure 41. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
